Maravai LifeSciences 3Q 2026: Revenue $45.85M — 10-Q Summary

Maravai LifeSciences’ third-quarter revenue rose year over year, while its net loss narrowed. Higher TriLink demand for research-use raw materials, Discovery mRNA and GMP consumables, along with CDMO strength and increased Cygnus demand for HCP and ELISA kits, lifted sales; lower costs and operatin…